In future studies, we will assess the efficacy of BBR to inhibit HIV infection in primary cells that are targets of HIV, such human peripheral blood mononuclear cells (PBMCs), CD4+ T cells, macrophages, microglia, and monocytes. This evidence concerns the gene CD4 and HIV infectious disease.